Atrial fibrillation is the most common heart rhythm disorder, affecting millions of people worldwide. Current treatment focuses on preventing stroke with blood thinners, controlling heart rate, and restoring normal rhythm through medications or procedures like ablation. Many people live normally with AFib, though it increases stroke risk and can cause fatigue and shortness of breath.
What's actually going on in research
Trials are testing new ablation techniques that create more precise scar patterns in the heart, pulsed field ablation that may reduce complications, and drugs that target specific ion channels to restore rhythm without affecting other organs. Researchers are also studying ways to predict who will develop AFib and testing early rhythm control to prevent heart damage.
Pulsed field ablation
This newer ablation technique uses electrical fields instead of heat or cold to destroy misfiring heart tissue. Early studies suggest it may work faster and cause less damage to nearby structures like the esophagus.
Early rhythm control
Studies are testing whether restoring normal rhythm soon after AFib starts prevents heart failure and other complications. The EAST trial showed that early treatment reduced stroke and hospitalization compared to waiting.
AI prediction tools
Researchers are developing algorithms that read standard EKGs to predict who will develop AFib before symptoms start. If validated, these tools could identify people who might benefit from preventive treatment.
What to know before you search
Eligibility typically depends on AFib type (paroxysmal, persistent, or permanent), how long you've had it, prior treatments including ablation, and other heart conditions.
What types of trials are currently open
- Ablation trials — Testing different ablation techniques — catheter-based, surgical, or hybrid — to see which best eliminates AFib with fewest complications.
- Drug trials — Testing new rhythm control medications and comparing strategies of rate control versus rhythm control for managing AFib.
- Blood thinner trials — Comparing newer blood thinners like apixaban and rivaroxaban to warfarin, and testing lower doses in specific populations.
- Device studies — Testing pacemaker-like devices that monitor heart rhythm or deliver small electrical pulses to prevent AFib episodes.
- Observational studies — Following people with AFib to understand what causes progression, which treatments work best long-term, and how lifestyle affects outcomes.
Recently added Atrial Fibrillation trials
Left Atrial and Left Ventricular Structural and Functional Evaluation by CCTA for Predicting Post-Ablation Outcomes in Patients With Atrial Fibrillation
This study aims to evaluate whether structural and functional parameters of the left atrium and left ventricle, measured by cardiac computed tomography angiography (CCTA), can predict clinical outcomes after radiofrequency ablation in patients with atrial fibrillation (AF). Atrial fibrillation is a common heart rhythm disorder, and while catheter ablation is an effective treatment, some patients experience recurrence. Current predictive tools have limitations. This prospective observational study will enroll patients with AF scheduled for first-time radiofrequency ablation. All participants will undergo CCTA before the ablation procedure to assess left atrial and left ventricular volumes, ejection fraction, and strain parameters. After ablation, patients will be followed for 12 months to monitor recurrence of atrial arrhythmias. The primary outcome is the recurrence of atrial fibrillation or atrial tachycardia lasting more than 30 seconds after a 3-month blanking period. The study will determine whether CCTA-derived parameters improve risk stratification for post-ablation recurrence. Findings may help identify patients who are more likely to benefit from ablation or who may need additional therapy.
The Clinical Outcomes and Therapeutic Effects in Patients With Cardiac Implantable Electronic Device-detected Subclinical and Clinical Atrial Fibrillation.
Atrial high-rate episodes (AHREs) detected by cardiac implantable electronic devices (CIEDs) are associated with an increased risk of progression to clinical atrial fibrillation (AF), stroke, heart failure, and mortality. However, optimal management strategies for patients with AHREs lasting between 6 minutes and 24 hours remain uncertain. Current guidelines recommend risk factor modification, but the role of early rhythm-control therapy in preventing AHRE progression has not been well established. This prospective, randomized, open-label study aims to evaluate whether a rhythm-control strategy combined with optimal risk factor management can reduce progression to sustained AHREs (≥24 hours) or clinical AF compared with optimal risk factor management alone in patients with device-detected AHREs. Eligible participants with CIED-detected AHREs lasting 6 minutes to 24 hours and without prior clinical AF will be randomly assigned to either a rhythm-control group or a usual-care group. The primary endpoint is progression to AHRE duration ≥24 hours or documented clinical AF. Secondary endpoints include stroke, systemic embolism, heart failure hospitalization, cardiovascular death, and all-cause mortality.
Find Atrial Fibrillation trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.